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OBJECTIVE—The objective of this study was to determine how
increasing the hepatic glycogen content would affect the liver’s
ability to take up and metabolize glucose.
RESEARCH DESIGN AND METHODS—During the ﬁrst 4 h of
the study, liver glycogen deposition was stimulated by intraportal
fructose infusion in the presence of hyperglycemic-normoinsuline-
mia. This was followed by a 2-h hyperglycemic-normoinsulinemic
control period, during which the fructose infusion was stopped,
and a 2-h experimental period in which net hepatic glucose
uptake (NHGU) and disposition (glycogen, lactate, and CO2)w e r e
measured in the absence of fructose but in the presence of a
hyperglycemic-hyperinsulinemic challenge including portal vein
glucose infusion.
RESULTS—Fructose infusion increased net hepatic glycogen
synthesis (0.7 6 0.5 vs. 6.4 6 0.4 mg/kg/min; P , 0.001), causing
a large difference in hepatic glycogen content (62 6 9v s .1 0 06
3 mg/g; P , 0.001). Hepatic glycogen supercompensation (fructose
infusion group) did not alter NHGU, but it reduced the percent of
NHGU directed to glycogen (79 6 4 vs. 55 6 6; P , 0.01) and
increased the percent directed to lactate (12 6 3v s .2 96 5; P =
0.01) and oxidation (9 6 3 vs. 16 6 3; P = NS). This change was
associated with increased AMP-activated protein kinase phosphor-
ylation, diminished insulin signaling, and a shift in glycogenic en-
zyme activity toward a state discouraging glycogen accumulation.
CONCLUSIONS—These data indicate that increases in hepatic
glycogen can generate a state of hepatic insulin resistance, which
is characterized by impaired glycogen synthesis despite pre-
served NHGU. Diabetes 60:398–407, 2011
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lthough excessive hepatic glucose production
contributes to fasting hyperglycemia (1,2), glu-
cose intolerance is also a major defect in hu-
mans with diabetes mellitus. In response to a
moderately sized oral glucose challenge, the liver normally
takes up approximately one third of the ingested glucose,
whereas the remaining two thirds escapes the splanchnic
bed and is metabolized by other tissues of the body (3–5).
Liver glucose disposal has consistently been shown to be
reduced in humans with diabetes mellitus (5–9), making it
important to understand how this process is regulated and
why it becomes dysfunctional.
Previous research has shown that net hepatic glucose
uptake (NHGU) is regulated by a number of factors, in-
cluding the glucose load to the liver, the hepatic sinusoidal
insulin concentration, and the route of glucose delivery into
the body. During euglycemic conditions, hyperinsulinemia
alone does little to stimulate NHGU (10) or net glycogen
synthesis (11), and only when pharmacologic levels of in-
sulin are present in the face of euglycemia is NHGU signif-
icantly stimulated (10). However, when the glucose load to
the liver is increased (i.e., hyperglycemia) by infusing glu-
cose into a peripheral vein, hyperinsulinemia increases
NHGU in a dose-dependent fashion (12). Despite this re-
lationship between the hepatic glucose load and insulin, a
rate of NHGU similar to that observed during the post-
prandial state (;5–6 mg/kg/min) can only be achieved during
hyperglycemic/hyperinsulinemic conditions when a portion
of the infused glucose is delivered via the hepatic portal
vein (13,14), thereby creating a negative arterial-portal vein
glucose gradient known as the “portal glucose signal.”
Some of the drugs now under development (e.g., gluco-
kinase [GK] activators, glucagon receptor antagonists, and
glycogen phosphorylase [GP] inhibitors) would reduce
postprandial glucose excursions by stimulating hepatic glu-
cose uptake and glycogen deposition. However, relatively
little is known about the impact of hepatic glycogen content
on the regulation of glucose metabolism in the liver in vivo.
Our previous study (15) showed that acutely increasing the
hepatic glycogen content by an increment similar to that
seen after a meal did not impair the response of the liver
(e.g., insulin signaling, NHGU, and net glycogen synthesis) to
a subsequent hyperglycemic/hyperinsulinemic challenge.
However, the increase in NHGU triggered by the increase in
insulin was small (1.6 mg/kg/min), as was the increment in
net glycogen synthesis (;1.0 mg/kg/min), raising the possi-
bility that these stimuli (increased insulin and glucose) were
not great enough to expose a defect caused by the increased
glycogen content. Furthermore, the hepatic glycogen level,
although high, was still within the normal diurnal range,
leaving open the possibility that decrements in NHGU or net
glycogen synthesis might not occur until the liver glycogen
content is increased to a greater extent. Therefore, in the
current study we increased the challenge to the liver by adding
portal glucose delivery to the hyperglycemic/hyperinsulinemic
challenge and further increased the hepatic glycogen content
to determine whether excessive liver glycogen can alter
hepatic glucose metabolism.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Animals and surgical procedures. Studies were carried out on healthy,
conscious 18-h fasted mongrel dogs of either sex with a mean weight of 22.5 6
0.4 kg. All animals were maintained on a diet of meat and chow (34% protein,
14.5% fat, 46% carbohydrate, and 5.5% ﬁber based on dry weight; ;1,700 kcal/d).
The animals were housed in a facility that met American Association for Ac-
creditation of Laboratory Animal Care guidelines, and the protocol was ap-
proved by Vanderbilt University’s Institutional Animal Care and Use Committee.
Two weeks before being studied, each dog underwent a laparotomy under
general anesthesia (0.01 mg/kg buprenorphine presurgery and ;2% isoﬂurane
inhalation anesthetic during surgery), and silicone catheters for sampling were
inserted in the hepatic vein, hepatic portal vein, and a femoral artery as de-
scribed previously (12). Catheters for intraportal infusion of hormones and
substrates were placed in the splenic and jejunal veins (each of which empties
into the portal vein), and ultrasonic ﬂow probes (Transonic Systems, Ithaca,
NY) were placed around the hepatic portal vein and the hepatic artery as
described previously (12).
Two days before each study, blood was drawn to determine the leukocyte
count and hematocrit for each animal. Animals were only studied if they had
a leukocyte count ,16,000/mm
3, a hematocrit .35%, a good appetite (as
evidenced by consumption of the entire daily ration), and normal stools.
On the morning of each study, catheters and ﬂow probe leads were exte-
riorized from subcutaneous pockets using local anesthesia (2% lidocaine,
Hospira, Lake Forest, IL). The contents of each catheter were aspirated and
then ﬂushed with saline. Angiocatheters (Deseret Medical, Becton Dickinson,
Sandy, UT) were inserted into the cephalic and saphenous veins to allow in-
fusion into the peripheral vasculature as desired. The animals stood com-
fortably in a Pavlov harness throughout the experiment.
Experimental design. Each experiment consisted of a 4-h liver glycogen
loading period (2360 to 2120 min), a 2-h control period (2120 to 0 min), and
a 2-h experimental period (0–120 min). Each experiment was initiated at minute
2360 by the infusion of somatostatin (SRIF; 0.8 mg/kg/min; Bachem, Torrance,
CA) into a peripheral vein to disable the endocrine pancreas (Fig. 1). This was
accompanied by the intraportal replacement of both insulin (0.3 mU/kg/min; Eli
Lilly & Co., Indianapolis, IN) and glucagon (0.55 ng/kg/min; Glucagen, Novo
Nordisk, Bagsvaerd, Denmark) at basal rates. At the same time, the hepatic
glucose load was doubled by infusing a 50% dextrose solution into a peripheral
vein and either 0.7% saline (moderately elevated [MOD]; n = 8) or fructose at
one of two rates (0.4 mg/kg/min; HIGH; n = 8, or 1.0 mg/kg/min; SC; n = 10) into
the portal vein. The latter was used so that we could stimulate NHGU and
glycogen deposition without altering plasma insulin levels. Thus, by the start of
the experimental period (i.e., at min 0), the hepatic glycogen content was
moderately elevated (MOD group), markedly elevated (HIGH), or supercom-
pensated (SC) relative to the level (;36 mg/g liver) (16) seen after an 18-h fast.
The 4-h glycogen loading period was followed by a 2-h hyperglycemic control
period during which fructose was not infused, but the basal hormone levels and
hyperglycemia were maintained. At 2120 min, a p-aminohippuric acid infusion
was started into a peripheral vein (0.4 mg/kg/min) to allow the assessment of
portal glucose infusate mixing with portal and hepatic vein blood during the
experimental period. A [
14C]glucose infusion (for assessment of glucose oxida-
tion) was begun at 290 min, so the tracer could equilibrate with blood glucose
before the experimental period. During the 2-h experimental period (0–120 min),
the intraportal infusion of insulin was increased to four times (1.2 mU/kg/min)
the basal rate, and 20% dextrose (mixed with p-aminohippuric acid) was infused
intraportally at a rate of 4.0 mg/kg/min. The preexisting hepatic glucose load was
maintained during the experimental period by reducing the infusion of 50%
dextrose into the peripheral vein as necessary. At the conclusion of the study,
animals were killed with an overdose of pentobarbital, the abdomen was
opened, and the positions of the catheter tips were veriﬁed. Liver and muscle
biopsies were immediately freeze clamped and stored at 280°C.
Processing and analysis of samples. The processing of blood samples has
been described (17). Plasma glucose was analyzed using the glucose oxidase
method (Analox Instruments; Lunenburg, MA). Insulin, glucagon, lactate,
glycerol, and nonesteriﬁed fatty acid concentrations were measured as pre-
viously described (14). Liver samples were pulverized under liquid nitrogen
and assayed for liver glycogen (18) and triglyceride (TG) (19,20) as described
previously. [
14C]glucose in plasma and
14CO2 content in whole blood were
measured as previously described (15). Western blot analyses were also car-
ried out as previously described (15,21), as were hepatic glycogen synthase
(GS) (under low or high glucose-6-phosphate [G6P], 0.16 and 6.67 mmol/L,
respectively, with 0.13 mmol/L of UDP-glucose) (22) and GP (23) activity
measurements and G6P levels (24).
Real-time PCR methods. RNA extraction, cDNA synthesis, SDS-PAGE, and
Western blotting were performed using standard methods (15,25). Real-time
PCR was performed using canine-speciﬁc primers for GK (25) fatty acid
synthase (FAS) (26), carnitine palmitoyltransferase (CPT) (27), and hypo-
xanthine phosphoribosyl transferase-1 (25). The PCR protocol consisted of
a denaturing cycle at 95°C for 2 min followed by a 35-cycle ampliﬁcation step
(95°C for 30 s, 55–60°C for 30 s, 72°C for 30 s). Expression of test genes were
normalized relative to the housekeeping gene hypoxanthine phosphoribosyl
transferase-1 using the Livak method as previously described (28). Analysis of
data was performed using iCycler iQ Optical System Software Version 5.0
(Bio-Rad Laboratories, Inc., Hercules, CA).
Calculations and data analysis. Hepatic blood ﬂow (HBF) was measured
using ultrasonic ﬂow probes. Net hepatic substrate balance, net hepatic fractional
substrate extraction, sinusoidal insulin and glucagon levels, and hepatic glucose
load were calculated as described previously (29). Plasma glucose levels were
converted to whole blood values as described previously for the calculation of
net hepatic glucose balance (NHGB) (30,31). Nonhepatic glucose uptake was
calculated as the sum of NHGB and the exogenous glucose infusion rate (GIR)
after correcting for the change in the glucose mass (32). Net hepatic glycogen
synthesis was calculated as (NHGU 2 fnet hepatic lactate output [NHLO] [in
glucose equivalents] + hepatic glucose oxidationg), where [NHGU] is the absolute
value of NHGB. The hepatic glucose oxidation rate was calculated by dividing the
net hepatic balance of
14CO2 by the arterial [
14C]glucose speciﬁc activity.
Statistical analysis. All data are presented as mean 6 SEM, and statistical
analyses were performed using SigmaStat (Aspire Software International;
Ashburn, VA) software. Clamp data were analyzed using 2-way repeated-
measures ANOVA (group 3 time), and 1-way ANOVA was used to compare
data from tissue analyses. Post hoc comparisons were made as appropriate,
and statistical signiﬁcance was P , 0.05.
RESULTS
Plasma hormone and glucose concentrations and
hepatic glucose and lactate metabolism
Glycogen loading period. During the glycogen loading
period, the arterial blood glucose level was 23 basal in
each group (Fig. 2A). On the other hand, the hepatic
FIG. 1. Schematic representation of the study. Portal fructose infusion rates of 0, 0.4, and 1.0 mg/kg/min represent the MOD, HIGH, and SC groups,
respectively.
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similar in all groups (Fig. 2B and C), as did HBF (Table 1).
NHGU, net glycogen synthesis, and NHLO were greater in
both fructose infusion groups than in the saline group (P ,
0.001; Fig. 2D–F). Likewise, both NHGU and net glycogen
synthesis were greater when fructose was infused at the
high rate as opposed to the low rate (P , 0.05).
Control and experimental periods. During the control
and experimental periods, total HBF was similar in all
groups (Table 1). Likewise, the arterial blood glucose level
and hepatic glucose loads were also similar between
groups (Fig. 3A and B). It was necessary to lower the ar-
terial glucose level slightly when the portal glucose in-
fusion was started to prevent the preexisting hepatic
glucose load from changing. The hepatic sinusoidal insulin
levels were increased fourfold at the outset of the exper-
imental period, whereas the hepatic sinusoidal glucagon
levels remained basal (Fig. 3C and D). As expected, NHGU
was modest (;2.0–2.6 mg/kg/min) during the last 30 min of
the control period regardless of treatment (Fig. 4A). Dur-
ing the experimental period, NHGU (Fig. 4A) and the he-
patic fractional extraction of glucose (data not shown)
increased rapidly and similarly in all groups. This increase
in NHGU was accompanied by an increase in the rate of
net glycogen synthesis and a reduction in NHLO (Fig. 4C),
whereas the rate of hepatic glucose oxidation remained
low in each group (Fig. 4D). The area under the curve
(AUC) during the ﬁnal hour (mg/kg $ 60 min) of the exper-
imental period for NHLO (28 6 7, 45 6 9, and 58 6 11 for
MOD, HIGH, and SC, respectively) and glucose oxidation
(15 6 3, 33 6 3, and 28 6 4, respectively) was signiﬁcantly
higher when liver glycogen was supercompensated
compared with MOD (P , 0.05), whereas the AUC for net
glycogen synthesis (182 6 39, 219 6 17, and 113 6 20,
respectively) was signiﬁcantly lower (P , 0.05). By using
AUC data over the ﬁnal 60 min of the experimental period
(Fig. 5), the percentage of NHGU accounted for by hepatic
glucose oxidation, lactate production, and net glycogen
synthesis averaged 9 6 3, 12 6 3, and 79 6 4%, respec-
tively, in MOD, 11 6 1, 15 6 3, and 74 6 3%, respectively,
in HIGH, and 16 6 3, 29 6 5, and 55 6 6%, respectively, in
SC. The percent of NHGU accounted for by net glycogen
synthesis and net lactate output was signiﬁcantly different
in SC compared with MOD (P , 0.01 for each).
Fat metabolism. Hyperglycemia modestly reduced arterial
FFA and glycerol in all groups during the glycogen loading
and control periods (Table 1). As expected, the fourfold in-
crease in plasma insulin reduced both further. No signiﬁcant
differences were detected between groups at any time.
Glucose infusion rate and nonhepatic glucose uptake.
During the glycogen loading period, the total GIR was
higher in both fructose infusion protocols than in the sa-
line infusion protocol. Likewise, it was higher in SC than
HIGH (P , 0.05; Table 1). However, during the control
period GIR returned to a similar rate in all groups. Like-
wise, the GIR increased similarly in response to insulin
infusion and portal glucose delivery in all groups. Non-
hepatic glucose uptake (Table 1) was not different be-
tween groups during the fructose infusion or control
periods, and increased similarly during the experimental
period in all groups.
Hepatic tissue data. There was a dose-dependent effect
of fructose on the hepatic glycogen level measured at the
end of the study (62 6 9, 86 6 8, and 100 6 3 mg/g for
FIG. 2. Arterial blood glucose (A), hepatic sinusoidal insulin (B), hepatic sinusoidal glucagon (C), NHGU (D), net hepatic glycogen synthesis (E),
and NHLO (in glucose equivalents) (F) during the ﬁnal 20 min of the 4-h glycogen loading period. *P < 0.05 compared with MOD; #P < 0.05
compared with HIGH.
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group; Fig. 6A). On the other hand, the skeletal muscle
glycogen level was similar in the three groups (8 6 1, 9 6 1,
and 9 6 1 mg/g, respectively; P . 0.05). Hepatic insulin
signaling was reduced when the glycogen level was
supercompensated as indicated by a 45% reduction in the
phosphorylation state of Akt (Fig. 6B) and a 21% reduction
in GSK3-b phosphorylation (Fig. 6C). This was associated
with an increase in hepatic G6P content in SC compared
with both MOD and HIGH (50 6 7, 66 6 7, and 176 6 46
nmol/g in MOD, HIGH, and SC, respectively; P , 0.01 for
each). In addition, there was a marked increase in AMP-
activated protein kinase (AMPK)-Thr172 phosphorylation
in SC compared with MOD (1.0 6 0.3, 1.1 6 0.3, and 2.3 6
0.3 in MOD, HIGH, and SC, respectively; P , 0.05; Fig. 6D)
and a reduction in liver GK mRNA (1.0 6 0.1, 1.1 6 0.1, and
0.6 6 0.1 in MOD, HIGH, and SC, respectively; P , 0.05) in
SC compared with MOD. The activity ratio of GS de-
creased 85% in SC compared with MOD (P , 0.05),
whereas the activity ratio of GP was increased fourfold in
SC compared with MOD (P , 0.05; Fig. 6E and F). Liver
TG content was not signiﬁcantly different among groups
(1.0 6 0.2, 1.1 6 0.2, and 1.5 6 0.5 mg TG/mg tissue for
MOD, HIGH, and SC groups, respectively; P . 0.40). The
slightly (but not signiﬁcantly) higher TG value in the SC
group was attributable to a single outlier (4.6 mg/mg), the
removal of which would make the SC group mean 1.0 6
0.1 mg/mg. Likewise, there were no differences in FAS
protein or the phosphorylation state of ATP-citrate lyase,
which are thought to be rate limiting for lipogenesis (data
not shown). Furthermore, there was no indication of
changes in the mRNA levels for selected enzymes involved
in the regulation of lipid metabolism, such as CPT-1 (1.0 6
0.2, 0.7 6 0.2, and 0.9 6 0.1) or FAS (1.0 6 0.2, 1.0 6 0.1
and 1.2 6 0.1) in MOD, HIGH, and SC, respectively.
DISCUSSION
The purpose of this study was to determine whether in-
creasing the hepatic glycogen content can limit the uptake
or storage of glucose by the liver. Our previous study (15)
showed that an increase in hepatic glycogen by an amount
similar to that seen after a single meal had no subsequent
effect on NHGU or hepatic glucose disposition in response
to a hyperglycemic/hyperinsulinemic clamp (i.e., without
FIG. 3. Arterial blood glucose (A), glucose load to the liver (B), hepatic sinusoidal insulin (C), and hepatic sinusoidal glucagon (D) before and
during the 120-min experimental period. No differences were detected among groups at any time point (P > 0.05).
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creased the hepatic glycogen content even further, and we
increased the challenge to the liver by adding portal glucose
delivery to the hyperglycemic/hyperinsulinemic signals pre-
viously used. Our data show that although acutely super-
compensating the hepatic glycogen content failed to affect
NHGU, it reduced net hepatic glycogen synthesis, resulting
in increased hepatic lactate production and glucose oxida-
tion. Furthermore, these changes were associated with the
generation of an insulin-resistant state in the liver, a signiﬁ-
cant increase in hepatic AMPK phosphorylation, and a shift
in the activity of glycogen metabolizing enzymes to a state
limiting further glycogen deposition.
Consistent with a previous study from our laboratory
(15), a catalytic dose of fructose was infused on the
background of hyperglycemia to load the liver with gly-
cogen. When small quantities of fructose accompany hy-
perglycemia, hepatic glucose metabolism is augmented in
both humans and dogs (33–35). In addition, it has been
shown in the dog that fructose stimulates liver glucose
uptake in a curvilinear fashion up to a rate (e.g., ;12.5 mg/
kg/min) (35) twice that generated during the postprandial
state (;5–6 mg/kg/min) (13,14). The potency of fructose
and the rapid diminution of its effect made it preferable to
insulin for liver glycogen loading because the latter stim-
ulates NHGU to a lower Vmax (15) and produces in-
tracellular signaling effects that can persist for a prolonged
period. On the basis of our estimate of the rate of glycogen
synthesis during the ﬁnal experimental period and the
hepatic glycogen level present at the end of the experi-
ment, we can estimate that the glycogen level that existed
before the insulin/glucose challenge was 52, 73, and 94 mg/g
liver in MOD, HIGH, and SC, respectively. The fact that
the net glycogen synthetic rates evident at the end of the
glycogen loading period in the two fructose infusion
groups (Fig. 2) were more similar than the liver glycogen
levels before the experimental period is most likely
explained by a slower rate of increase in glycogen syn-
thesis over the 4-h loading period in the group with the
lower fructose infusion rate and the more rapid return of
FIG. 4. NHGU (A), net hepatic glycogen synthesis (B), NHLO (in glucose equivalents) (C), and hepatic glucose oxidation (D) during the ex-
perimental period. AUC during the ﬁnal hour of the experimental period for hepatic glucose oxidation (P = 0.01) and NHLO (P = 0.02) was lower in
MOD compared with SC, whereas hepatic glycogen synthesis was higher (P = 0.05).
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fructose infusion.
As noted earlier, we previously showed that moderate
differences in liver glycogen content did not impair NHGU
or net liver glycogen synthesis seen in response to
hyperglycemic/hyperinsulinemic conditions (15). This ﬁnd-
ing was in contrast with that of Galassetti et al. (16), who
showed that although lowering the glycogen content by
FIG. 5. The disposition of glucose taken up by the liver during the ﬁnal hour of the experimental period into carbon dioxide (CO2; bricked area),
lactate (hatched area), and glycogen (dotted area). *P < 0.05 for net hepatic glycogen synthesis and NHLO in SC compared with both HIGH and
MOD.
FIG. 6. Hepatic glycogen content (A), Akt (B), GSK3-b (C), and AMPK (D) phosphorylation and GS (E) and GP (F) activity ratios from liver
biopsies taken at the conclusion of the experimental period. *P < 0.05 compared with MOD; #P < 0.05 compared with HIGH.
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the proportion of NHGU that was converted to glycogen.
Unfortunately, the prolonged fast undoubtedly produced
changes in hepatic glucose metabolism that were inde-
pendent of the glycogen content, making data interpreta-
tion difﬁcult. Our current results demonstrate that although
supercompensation of the liver’s glycogen stores (i.e., 100 6
3 vs. 62 6 9 mg/g liver) had no effect on NHGU, it reduced
net glycogen synthesis signiﬁcantly, with 65% of this re-
duction being accounted for by increased lactate pro-
duction, and the remainder by a near doubling of glucose
oxidation. These data suggest that as glycogen stores be-
come saturated, glucose taken up by the liver is directed
away from glycogen in favor of the glycolytic pathway,
such that lactate is subsequently released into the circu-
lation to be metabolized by other tissues of the body. Our
data, together with those of Galassetti et al. (16), suggest
that hepatic glycogen synthesis displays autoregulatory
behavior, being more efﬁcient when the glycogen content
is low (i.e., ,30 mg/g liver) and less efﬁcient when it is
high (i.e., .100 mg/g liver) but of ﬁxed efﬁciency over the
normal diurnal range of glycogen concentrations.
In contrast with studies that have shown a reduction in
muscle glucose uptake associated with increased glycogen
content (36,37), liver glucose uptake likely remains un-
affected by increased glycogen content because its glucose
transport proteins are indigenous to the membrane, thereby
making their activity independent of insulin signaling.
However, we did see a reduction in GK mRNA in the SC
group that was likely caused by impaired insulin signaling.
Had the duration of the metabolic challenge period been
.2 h, GK protein would likely have been reduced and liver
glucose uptake would in turn be expected to decrease.
The decrease in glycogen deposition in the super-
compensated liver is most likely explained both by the
increase in AMPK phosphorylation and by the impairment
in insulin signaling. Jørgensen et al. (38) showed that in-
creasing the glycogen content of skeletal muscle led to
large increases in GS phosphorylation at Ser7, thereby
reducing its activity. In line with this, McBride and Hardie
(39) hypothesized that glycogen loading (in both muscle
and liver) increases the binding of AMPK to the non-
reducing ends of the glycogen molecule’s outer chains, and
this close proximity to GS, which is also bound to glyco-
gen, allows AMPK to reduce GS activity by phosphorylat-
ing it at Ser7. The AMPK activator AICAR has been
reported to reduce insulin-mediated Akt and GSK3-b
phosphorylation in muscle (40). Whether the increase in
hepatic AMPK was responsible for the decrease in insulin
signaling and GSK3-b phosphorylation in the current study
remains unclear. Regardless, it seems likely that the de-
crease in GSK3-b phosphorylation that we observed could
also have contributed to the decrease in GS activity. Fu-
ture studies will be required to establish a cause and effect
relationship among AMPK, hepatic insulin signaling, GS
activity, and glycogen deposition.
In concert with the reduction in GS activity, there was
as i g n i ﬁcant increase in GP activity, and undoubtedly these
coordinated changes were responsible for the reduction in
net hepatic glycogen synthesis. Previous studies have
shown that AICAR has little effect on GP activity (i.e., the
phosphorylation state of GP) (41–43). On the other hand, it
is also worth noting that in a previous study, Hallgren et al.
(44) showed that an increase in the intracellular particulate
concentration, which is indicative of cell shrinkage, can
cause an increase in GP activity by a magnitude similar to
that observed in response to glucagon. An approximate
threefold increase in the hepatic glycogen content above
basal may also be able to bring about such a response.
Despite the large reduction in GS activity, the liver was
still able to incorporate more than one half of the glucose
taken up in response to the hyperglycemic/hyperinsulinemic
challenge into glycogen. This relative (albeit incomplete)
preservation of the glycogen synthetic rate was probably
a result of the 3.5-fold increase in hepatic G6P content that
was generated by the “bottlenecking” of incoming glucose
caused by the reduction in glycogen synthesis. The GS
activity ratio (i.e., the ratio of glycogen synthesis at low
compared with high G6P levels) represents the phos-
phorylation state of the enzyme and does not account for
differences in allosteric effectors that may exist in vivo. In
addition to being a potent stimulator of glycolysis and
lactate production in the liver, G6P activates GS without
regard to its state of phosphorylation (45). Thus, GS ac-
tivity in vivo was probably greater in the SC group than is
reﬂected by the in vitro assay because of the elevated G6P
content. During the ﬁnal 20 min of the glycogen loading
period, the percentage of NHGU that was converted to
glycogen in the two fructose infusion groups was similar
(69 vs. 70% in HIGH and SC, respectively), despite a large
calculated difference (59 6 8 vs. 82 6 3 mg/g liver) in
hepatic glycogen content. The most likely explanation for
this is that the hepatic glycogen content present at the
end of the glycogen loading period in the supercom-
pensated group still had not reached a level high enough
to trigger the inhibition of glycogen deposition. The fact
that there was only a small, nonsigniﬁcant effect of in-
c r e a s e dg l y c o g e no ng l u c o s ed i s p o s i t i o ni nt h eH I G H
group supports this possibility. On the other hand, it is
also possible that the G6P effect on GS is not down-
regulated by glycogen saturation, and it was probably this
signal that triggered glycogen synthesis during the gly-
cogen loading period.
Although fructose can be lipogenic in the liver, the nor-
mal rate of hepatic de novo lipogenesis (DNL) from car-
bohydrate precursors is low (46) and becomes dysregulated
only after chronic fructose consumption (47,48). In line with
this, Parks et al. (49) showed that a morning meal in which
50% of the caloric intake was from fructose did not affect
DNL during a mixed meal consumed ;4.5 h later. In our
study, fructose made up ,5 and 10% of calories infused
during the glycogen loading period in the HIGH and SC
groups, respectively, and would therefore not have been
expected to increase DNL signiﬁcantly. The absence of
differences in hepatic TG content and in FAS and CPT-1
mRNA, and the similarity of FAS and ATP-citrate lyase
protein content and phosphorylation state in all groups
support our conclusion that relevant quantities of carbon
derived from NHGU do not end up in hepatic lipid stores.
In summary, our data show that although a modest in-
crease in the hepatic glycogen content has little effect on
liver glucose uptake or glycogen accretion, a marked in-
crease in hepatic glycogen reduces net glycogen synthesis.
Consequently, both lactate output and glucose oxidation
by the liver increase. These changes are associated with
impaired hepatic insulin signaling, increased AMPK phos-
phorylation, and a change in the activity of glycogen me-
tabolizing enzymes toward a state that discourages further
glycogen accumulation. Thus, as drugs that increase he-
patic glycogen stores (e.g., GK activators, glucagon re-
ceptor antagonists, and GP inhibitors) are developed to
treat postprandial hyperglycemia in patients with type 2
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